Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$79.29 USD

79.29
1,037,884

-1.20 (-1.49%)

Updated Nov 7, 2024 03:59 PM ET

After-Market: $79.32 +0.03 (0.04%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Varian (VAR) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

Varian (VAR) expects revenue growth in the range of 9-10% for fiscal 2019.

Cerner (CERN) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Cerner (CERN) Q2 results benefit from higher revenues, gains in Licensed software, Professional and Managed services units, and gross margin expansion.

Thermo Fisher (TMO) Beats on Q2 Earnings, Lifts Guidance

by Zacks Equity Research

Banking on a strong operational performance, Thermo Fisher (TMO) raises its 2019 revenue and earnings guidance.

Neogen's (NEOG) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Neogen's (NEOG) strong international business and solid performance by core Food Safety segment resulted in year-over-year revenue growth.

Boston Scientific (BSX) Q2 Earnings Top on Growth in All Lines

by Zacks Equity Research

Boston Scientific's (BSX) revenue strength across all business lines and geographies raises investors' optimism on the stock.

Medidata (MDSO) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

Medidata (MDSO) gains from solid segmental contributions in Q2.

Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View

by Zacks Equity Research

Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.

Can Breast Health Growth Aid Hologic (HOLX) in Q3 Earnings?

by Zacks Equity Research

Hologic (HOLX) is expected to deliver strong third-quarter fiscal 2019 results on robust performance of the breast health segment.

Quest Diagnostics (DGX) Q2 Earnings, Revenues Beat Estimates

by Zacks Equity Research

We are upbeat about Quest Diagnostics' (DGX) expanded network access which has helped accelerate volume growth in the second quarter.

Why the Earnings Surprise Streak Could Continue for Hologic (HOLX)

by Zacks Equity Research

Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Abbott (ABT) Tops Q2 Earnings Estimates, Lifts EPS Guidance

by Zacks Equity Research

Abbott (ABT) registers strong Cardiovascular and Neuromodulation sales on double-digit growth in Electrophysiology, Heart Failure and Structural Heart.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for July 17th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

HOLX vs. TCMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

HOLX vs. TCMD: Which Stock Is the Better Value Option?

Sreyoshi Mukherjee headshot

Women Health a Top Priority Now: 3 Stocks to Watch

by Sreyoshi Mukherjee

Women's healthcare gains global importance, investors might want to keep an eye on these stocks.

Urmimala Biswas headshot

5 Best GARP Stocks With Discounted PEG

by Urmimala Biswas

A lower PEG ratio, preferably less than 1, is always better for GARP investors.

Veracyte (VCYT) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Hologic (HOLX) is generating consistent positive results, courtesy of growth initiatives.

Hologic (HOLX) Inks Deal to Acquire SuperSonic Imagine

by Zacks Equity Research

The acquisition of SuperSonic Imagine is in sync with Hologic's (HOLX) strategy to provide wide-ranging screening, interventional and surgical solutions.

HOLX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Hologic (HOLX) Down 5.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Hologic Breast Health Arm Aids Strongly, Rising Costs Ail

by Zacks Equity Research

Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.

HOLX vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

Hologic (HOLX) registers solid Q1year-over-year revenue growth in core businesses like Breast Health and Molecular Diagnostics.

Hologic (HOLX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 1.75% and 1.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?